| Information flow in the pharmaceutical supply chain N Yousefi, A Alibabaei Iranian journal of pharmaceutical research: IJPR 14 (4), 1299, 2015 | 77 | 2015 |
| Knowledge, attitude and practice of pharmacists regarding dietary supplements: a community pharmacy-based survey in Tehran G Mehralian, N Yousefi, F Hashemian, H Maleksabet Iranian journal of pharmaceutical research: IJPR 13 (4), 1457, 2014 | 66 | 2014 |
| New Product Development in the Pharmaceutical Industry: Evidence from a generic market N Yousefi, G Mehralian, HR Rasekh, M Yousefi Iranian journal of pharmaceutical research: IJPR 16 (2), 834, 2017 | 46 | 2017 |
| A review of achievements and challenges of Iran’s health transformation plan M Peikanpour, S Esmaeli, N Yousefi, A Aryaeinezhad, H Rasekh Payesh 17 (5), 481-494, 2018 | 36 | 2018 |
| Reasons for physicians’ tendency to irrational prescription of corticosteroids N Yousefi, R Majdzadeh, M Valadkhani, S Nedjat, H Mohammadi Iranian Red Crescent Medical Journal 14 (11), 713, 2012 | 33 | 2012 |
| Consumers’ perception of generic substitution in Iran N Yousefi, G Mehralian, F Peiravian, S NourMohammadi International Journal of Clinical Pharmacy 37, 497-503, 2015 | 26 | 2015 |
| Policies to improve access to pharmaceutical products in shortage: the experience of Iran food and drug administration N Yousefi, N Moradi, R Dinarvand, G Ghiasi, H Inanloo, F Peiravian DARU Journal of Pharmaceutical Sciences 27, 169-177, 2019 | 19 | 2019 |
| The effect of organizational resilience and strategic foresight on firm performance: competitive advantage as mediating variable M Fathi, N Yousefi, H Vatanpour, F Peiravian Iranian Journal of Pharmaceutical Research: IJPR 20 (4), 497, 2021 | 18 | 2021 |
| Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison S Taheri, MA Sahraian, N Yousefi Journal of Medical Economics 22 (1), 71-84, 2019 | 17 | 2019 |
| Pharmaceutical innovation and market share: evidence from a generic market N Yousefi, G Mehralian, HR Rasekh, H Tayeba International Journal of Pharmaceutical and Healthcare Marketing 10 (4), 376-389, 2016 | 13 | 2016 |
| Physicians’ perceptions of generic medicine in Iran N Yousefi, G Mehralian, F Peiravian, S Jahangiri, R Ahmadi Drugs & Therapy Perspectives 31, 244-250, 2015 | 12 | 2015 |
| Investigation the determinants of pharmaceutical expenditure share of GDP in Iran and selected OECD countries A Kadkhodamanesh, V Varahrami, L Zarei, F Peiravian, M Hadidi, ... Journal of Pharmaceutical Policy and Practice 14 (1), 82, 2021 | 11 | 2021 |
| Physicians’ loyalty to branded medicines in low-middle-income countries: A structural equation modeling G Mehralian, Z Sharif, N Yousefi, M Akhgari Journal of Generic Medicines 13 (1), 9-18, 2017 | 11 | 2017 |
| Generic substitution policy implementation: A pharmacists' perspective survey N Yousefi, G Mehralian, F Peiravian, F Noee Journal of generic medicines 12 (1), 17-25, 2015 | 10 | 2015 |
| Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis S Taheri, F Mirzayeh Fashami, F Peiravian, N Yousefi Iranian journal of pharmaceutical research 18 (2), 1073-1085, 2019 | 9 | 2019 |
| Country pharmaceutical situation on access, quality, and rational use of medicines: An evidence from a middle-income country H Minaei, M Peikanpour, N Yousefi, P Peymani, F Peiravian, N Shobeiri, ... Iranian Journal of Pharmaceutical Research: IJPR 18 (4), 2191, 2019 | 9 | 2019 |
| Intellectual resource and new product performance: mediating role of innovation capability N Yousefi, R Ahmady, G Mehralian International Journal of Learning and Intellectual Capital 19 (2), 154-168, 2022 | 8 | 2022 |
| Evaluation of efficiency enhancement in Iran Health Insurance Organization: a policy brief for pharmaceutical cost containment N Yousefi, M Polroudi Moghaddam, G Afsharmanesh, F Peiravian The International Journal of Health Planning and Management 35 (6), 1503-1511, 2020 | 7 | 2020 |
| Efficacy and safety of dulaglutide compared to liraglutide: A systematic review and meta-analysis in patients with type 2 diabetes mellitus S Taheri, A Saffaei, B Amani, A Akbarzadeh, F Peiravian, N Yousefi Iranian journal of pharmaceutical research: IJPR 18 (4), 2180, 2019 | 5 | 2019 |
| Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review G Mohammadnezhad, B Azadmehr, M Mirheidari, N Yousefi Cost Effectiveness and Resource Allocation 20 (1), 62, 2022 | 4 | 2022 |
